<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chagas disease: Epidemiology, screening, and prevention</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chagas disease: Epidemiology, screening, and prevention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chagas disease: Epidemiology, screening, and prevention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Caryn Bern, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter F Weller, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 08, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chagas disease is caused by infection with the protozoan parasite <em>Trypanosoma cruzi</em> [<a href="#rid1">1-3</a>]. Most infected patients are asymptomatic; late manifestations include heart disease and gastrointestinal disease.</p><p>Issues related to the epidemiology, screening, and prevention of Chagas disease will be reviewed here. Other issues related to Chagas disease are discussed in detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/114181.html" rel="external">"Chagas disease: Acute and congenital Trypanosoma cruzi infection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/114192.html" rel="external">"Chagas disease: Chronic Trypanosoma cruzi infection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4955.html" rel="external">"Chronic Chagas cardiomyopathy: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/4925.html" rel="external">"Chronic Chagas cardiomyopathy: Management and prognosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5700.html" rel="external">"Chagas gastrointestinal disease"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY AND VECTORIAL TRANSMISSION</span><span class="headingEndMark"> — </span>Chagas disease is responsible for a higher burden of morbidity and mortality than any other parasitic disease in the Western hemisphere, including malaria [<a href="#rid4">4</a>]. Vector-borne transmission is the major route of Chagas transmission. Transmission can also occur vertically from mother to fetus, via ingestion of contaminated food or drink, via transfusion of infected blood components, via transplantation of an organ from an infected donor, or via laboratory exposure [<a href="#rid5">5</a>]. In the absence of successful antitrypanosomal treatment, infection is lifelong; spontaneous cure is extremely rare. </p><p class="headingAnchor" id="H687327901"><span class="h2">Geographic distribution</span><span class="headingEndMark"> — </span>Chagas disease is endemic in 21 continental Latin American countries, from the southern United States to the north of Argentina and Chile. Vector-borne transmission occurs exclusively in the Americas, where an estimated 6 million people are infected (<a class="graphic graphic_table graphicRef58263" href="/z/d/graphic/58263.html" rel="external">table 1</a>) [<a href="#rid6">6</a>]. Historically, the disease occurred predominantly in rural areas of Latin America where residents of infested houses were repeatedly exposed to infected vectors [<a href="#rid2">2,5</a>]. The prevalence of <em>T. cruzi</em> is highest in Bolivia, Argentina, Paraguay, Ecuador, El Salvador, and Guatemala [<a href="#rid1">1,6</a>].</p><p class="headingAnchor" id="H3989575381"><span class="h2">Vector transmission and life cycle</span><span class="headingEndMark"> — </span>Parasite transmission via infected triatomine bugs is responsible for the majority of infections (<a class="graphic graphic_figure graphicRef53632" href="/z/d/graphic/53632.html" rel="external">figure 1</a> and <a class="graphic graphic_picture graphicRef66260" href="/z/d/graphic/66260.html" rel="external">picture 1</a>). Vector control programs are discussed elsewhere. (See <a class="local">'Vector control'</a> below.)</p><p>The infective trypomastigote form of the <em>T. cruzi </em>parasite is present in large numbers in the feces of infected triatomine bugs. During or immediately after a blood meal, the triatomine bug defecates on the skin of the host, allowing the organism to enter through the bite wound. The organism can also enter via intact conjunctiva or mucous membranes. Most domestic triatomine species feed nocturnally and are able to complete their blood meal without awakening the host [<a href="#rid7">7</a>].</p><p>The classic epidemiology of vector-borne <em>T. cruzi</em> is closely linked to the biologic and ecologic characteristics of the triatomine vectors and the reservoir hosts (including both domestic and sylvatic mammals). The triatomine passes through five nymphal stages; only the adults are winged. Triatomine bugs of both sexes must take blood meals to develop through their nymphal stages to adults. In addition, females require blood meals to lay eggs. Thus, both nymphs and adults, of both sexes, may be infected with <em>T. cruzi</em>, but infection rates increase with developmental stage and age.</p><p><em>T. cruzi</em> infection is transmitted to wild mammals by sylvatic triatomine species; these bugs often colonize the nests of rodent or marsupial reservoir hosts [<a href="#rid7">7,8</a>]. Sylvatic triatomine adults may fly into human dwellings and cause sporadic human infections [<a href="#rid9">9</a>].</p><p>Domestic transmission occurs in settings where triatomine vectors have become adapted to living in human dwellings and nearby animal enclosures. Domestic mammals such as dogs, cats, and guinea pigs play important roles as triatomine blood meal sources and <em>T. cruzi</em> reservoir hosts [<a href="#rid10">10-12</a>]. Some triatomine species can infest both domestic and sylvatic sites [<a href="#rid13">13</a>]. Triatomines also may feed on blood from birds and reptiles but these animals are not susceptible to <em>T. cruzi</em> infection.</p><p>There are more than 130 triatomine bug species in the Americas, many of which can transmit <em>T. cruzi</em> [<a href="#rid7">7,8</a>]. A small number of highly domiciliated vectors are of disproportionate importance in the human epidemiology of disease (<a class="graphic graphic_table graphicRef73573" href="/z/d/graphic/73573.html" rel="external">table 2</a>) [<a href="#rid14">14</a>]. In Mexico and Central America, the main domestic and peridomestic vector is <em>Triatoma dimidiata</em>. In northern South America, <em>Rhodnius prolixus</em> occurs in both domestic and sylvatic cycles [<a href="#rid15">15</a>]. <em>R. prolixus</em> has been certified as eliminated from Central America [<a href="#rid16">16</a>]. In Brazil, Bolivia, and farther south, the main domestic vector is <em>Triatoma infestans</em>. <em>Panstrongylus megistus</em> is an important domestic vector in Brazil and is found as a sylvatic vector in Bolivia, Paraguay, and Argentina (<a class="graphic graphic_table graphicRef73573" href="/z/d/graphic/73573.html" rel="external">table 2</a>) [<a href="#rid17">17</a>]. </p><p>Poor-quality housing with adobe or unfinished brick walls provides crevices and other hiding places for triatomine bugs [<a href="#rid18">18,19</a>]. Roofs made of thatch are an attractive habitat for several species [<a href="#rid20">20</a>]. Domestic infestation rates in endemic areas can be high (eg, 25 to 100 percent of houses infested). A house and its immediate surroundings may support large colonies of both juvenile and adult bugs [<a href="#rid18">18,19,21</a>].</p><p>In endemic settings, <em>T. cruzi</em> infection is usually acquired in childhood. Infection persists for life, so the seroprevalence in an area with sustained vector-borne transmission increases with age (reflecting cumulative incidence) [<a href="#rid22">22,23</a>]. Before widespread vector control was instituted in the early 1990s, more than 60 percent of adults were infected with <em>T. cruzi</em> in some endemic communities [<a href="#rid21">21,24</a>]. Cross-sectional community surveys have demonstrated that most infected individuals are asymptomatic (have the indeterminate form); an estimated 70 to 80 percent remain asymptomatic throughout their lives [<a href="#rid5">5,25</a>]. The prevalence of clinical disease increases with age, reflecting onset of cardiac and gastrointestinal manifestations in early adulthood with progression over a period of years to decades [<a href="#rid26">26,27</a>].</p><p>The southern region of the United States has established enzootic cycles of <em>T. cruzi</em> involving several triatomine vector species and mammalian hosts, such as raccoons, opossums, woodrats, and domestic dogs [<a href="#rid28">28-31</a>]. Autochthonous vector-borne infections in humans have been documented in Texas, California, Tennessee, Louisiana, Mississippi, Arizona, and Missouri [<a href="#rid3">3,32-39</a>]. The rarity of vector-borne transmission in the United States has been attributed to housing conditions that minimize vector-human contact and lower transmission efficiency of the North American vectors [<a href="#rid33">33,40</a>]. A study of repeat blood donors in the United States demonstrated no locally acquired incident infections over 6 million person-years of follow-up, confirming that autochthonous vector-borne transmission is rare [<a href="#rid41">41</a>]. However, undetected cases certainly occur. </p><p class="headingAnchor" id="H170459409"><span class="h2">Changes due to migration and public health interventions</span><span class="headingEndMark"> — </span>The epidemiology of Chagas disease has changed due to migration of individuals within and outside of endemic countries as well as successful programs to reduce transmission in endemic areas [<a href="#rid2">2</a>]. The following factors have altered the epidemiology of Chagas disease:</p><p class="bulletIndent1"><span class="glyph">●</span>Massive rural to urban migration within Latin America</p><p class="bulletIndent1"><span class="glyph">●</span>International migration of persons from Chagas disease-endemic areas to Europe and the United States</p><p class="bulletIndent1"><span class="glyph">●</span>Rise of the human immunodeficiency virus (HIV) epidemic</p><p class="bulletIndent1"><span class="glyph">●</span>Success of vector control in many areas</p><p class="bulletIndent1"><span class="glyph">●</span>Failure of vector control and emergence of insecticide resistance, especially in the Gran Chaco</p><p></p><p>There are several consequences of these trends. Hundreds of thousands of infected individuals live in cities across Latin America and in the United States, Spain, and other European countries [<a href="#rid42">42,43</a>]. In Santa Cruz (the largest city in Bolivia), <em>T. cruzi</em> infection is found in 15 to 20 percent of pregnant women presenting for delivery and up to 60 percent of patients with heart disease [<a href="#rid44">44,45</a>]. An estimated 300,000 infected immigrants are thought to be living in the United States [<a href="#rid42">42,46</a>]; the prevalence of Chagas disease among Latin American-born residents of Los Angeles County was estimated to be 1.24 percent in one study [<a href="#rid47">47</a>]. In studies of Latin American immigrants presenting to health care facilities with cardiac disease, the prevalence of <em>T. cruzi</em> infection has ranged from 5 to 19 percent and is highest in patients with dilated cardiomyopathy [<a href="#rid48">48-51</a>]. Because of infection prevalence and immigration patterns, <em>T. cruzi</em> infection in the United States is most commonly found in immigrants from El Salvador and Mexico [<a href="#rid47">47</a>]. At least 40,000 infected individuals live in Spain; the largest affected group are immigrants from Bolivia [<a href="#rid43">43,52</a>].</p><p>In a study including more than 14 million units of blood screened between January 2007 and June 2008 in the United States, the overall seroprevalence was 1:27,500; the highest seroprevalence rates were observed in Florida and California [<a href="#rid53">53</a>]. Of 104 identified donors infected with <em>T. cruzi</em>, 28 percent were born in Mexico, 26 percent in the United States, 16 percent in El Salvador, and 11 percent in Bolivia; the remaining donors were born in nine other Central and South American countries. Among donors infected with <em>T. cruzi </em>who were<em> </em>born in the United States, 37 percent reported no specific risk factors for <em>T. cruzi</em> infection; all reported outdoor activities in the southern United States, suggesting autochthonous exposure to the infected vector or animal reservoirs. A subsequent study using blood bank screening data suggests that 5 to 7 percent of blood donors infected with <em>T. cruzi</em> may have been infected through local vector-borne transmission in the United States [<a href="#rid54">54</a>].</p><p>An additional consequence of these migration patterns is the occurrence of congenital and organ-derived <em>T. cruzi</em> infection in areas without vector-borne transmission. Congenital infections have been detected in the United States, Spain, and Switzerland, and transplant transmission of <em>T. cruzi</em> infection has occurred in the United States [<a href="#rid55">55-59</a>].</p><p>Movement of individuals infected with <em>T. cruzi</em> to cities has resulted in a rise in HIV coinfection [<a href="#rid60">60</a>]. Reactivation of Chagas disease in patients infected with <em>T. cruzi</em> and HIV has been described in Brazil, Bolivia, Argentina, and the United States [<a href="#rid60">60-64</a>].</p><p>The success of vector control means that formerly endemic areas of Brazil, Uruguay, Argentina, Paraguay, and Bolivia no longer have domestic and peridomestic vector-borne transmission [<a href="#rid5">5</a>]. Congenital transmission therefore accounts for a greater proportion of new infections than in the past; in 2015, the Pan American Health Organization estimated that 77 percent of incident infections are due to vectorial transmission compared with 22 percent by congenital transmission [<a href="#rid6">6</a>].</p><p>Insecticide resistance and failure of vector control methods in the Gran Chaco region of Bolivia, Argentina, and Paraguay means that this area still experiences the highest incidence of <em>T. cruzi</em> infection [<a href="#rid65">65</a>]. In much of this area, more than half of the rural population is infected [<a href="#rid23">23,66</a>]. Innovative approaches are needed to address vector control, etiologic treatment, and management of Chagas heart disease in this region.</p><p class="headingAnchor" id="H3200652730"><span class="h2">Molecular epidemiology</span><span class="headingEndMark"> — </span><em>T. cruzi</em> is recognized as a complex of seven major lineages (TcI-TcVI and TcBat), with discrete but overlapping distributions [<a href="#rid67">67-69</a>]. TcI is the principal cause of Chagas disease in Mexico, Central America, and northern South America [<a href="#rid70">70-72</a>], while TcII, TcV, and TcVI are more frequently isolated from domestic transmission cycles in southern South America [<a href="#rid15">15</a>].</p><p>Gastrointestinal Chagas disease has long been observed to occur with some frequency in the Southern Cone countries, but very rarely in Mexico, Central America, and northern South America; this distribution was observed to track closely with the related discrete typing units (DTUs) TcII, TcV, and TcVI versus the more distantly related TcI [<a href="#rid67">67</a>]. No other clinical outcome has been convincingly shown to be associated with differences in DTU. Cardiomyopathy occurs throughout the range of <em>T. cruzi</em>, and the distribution of genotypes in any given study does not differ between those with and without cardiomyopathy [<a href="#rid73">73</a>]. Similarly, congenital infections mirror the distribution of genotypes detected among local adult populations [<a href="#rid73">73</a>].</p><p>However, molecular data are much sparser from regions where TcI predominates, compared with the Southern Cone. Additional data are needed to determine whether rates of congenital Chagas disease differ by parasite lineage. One of the major challenges to such studies is the technical difficulty of genotyping directly from clinical specimens [<a href="#rid73">73</a>]. Serotyping has been suggested as an alternative, and a rapid test that detects TcII/TcV/TcVI has been developed [<a href="#rid74">74,75</a>]. The sensitivity of the rapid test was higher among those with cardiomyopathy compared with asymptomatic infected individuals, possibly reflecting higher antibody levels in symptomatic individuals [<a href="#rid75">75</a>]. A parallel serotyping tool for TcI has been developed [<a href="#rid76">76</a>]. Both serotyping and molecular typing are applicable only as research tools.</p><p class="headingAnchor" id="H591899160"><span class="h1">NONVECTORIAL TRANSMISSION</span></p><p class="headingAnchor" id="H1618493691"><span class="h2">Vertical transmission</span><span class="headingEndMark"> — </span>An estimated 22 percent of new Chagas infections occur through mother-to-child transmission [<a href="#rid6">6</a>]. Congenital transmission can occur via females who themselves were infected congenitally, perpetuating the disease in the absence of the vector [<a href="#rid77">77</a>].</p><p>Reported transmission rates from infected mothers to infants range from approximately 1 to 10 percent [<a href="#rid44">44,78-84</a>]. The low sensitivity of neonatal screening tests combined with low follow-up rates later in infancy may lead to substantial underestimation of the transmission rate; one study estimated that only half of all infected infants are detected by routine screening [<a href="#rid44">44</a>]. (See  <a class="medical medical_review" href="/z/d/html/114181.html" rel="external">"Chagas disease: Acute and congenital Trypanosoma cruzi infection", section on 'Congenital Chagas disease'</a>.)</p><p>The strongest determinant of vertical transmission risk is the level of parasitemia in the mother; females with negative polymerase chain reaction (PCR) results are very unlikely to transmit to their infants [<a href="#rid44">44,85,86</a>]. Other factors associated with increased risk of congenital transmission include younger maternal age and HIV infection, likely because they are associated with higher parasite loads [<a href="#rid44">44,78,83,85-90</a>]. Treatment of females <strong>prior to</strong> pregnancy significantly decreases parasitemia and reduces the risk of congenital transmission by an estimated 95 percent [<a href="#rid86">86,91,92</a>]. Diagnosis in females of reproductive age is therefore a high priority (see <a class="local">'Summary of screening recommendations'</a> below). Antitrypanosomal drugs are contraindicated during pregnancy and lactation; if the diagnosis is made during pregnancy, treatment should be postponed until lactation ends.</p><p>Congenital transmission has been reported in the United States and in Europe [<a href="#rid55">55,56,58,83,93</a>].</p><p class="headingAnchor" id="H2617628594"><span class="h2">Breastfeeding</span><span class="headingEndMark"> — </span>The risk of transmission of Chagas disease via breastfeeding is unknown, but appears to be low [<a href="#rid94">94</a>]. In general, mothers with acute or reactivated Chagas disease should not breastfeed. Breastfeeding is reasonable for mothers with chronic Chagas disease. However, for females with chronic Chagas disease, it is generally suggested that breastfeeding be interrupted if the nipples are fissured or bleeding; a reasonable alternative is expression and sterilization of breast milk by pasteurization or microwave cooking [<a href="#rid94">94</a>].</p><p>Data on the transmission of <em>T. cruzi</em> through lactation are limited [<a href="#rid94">94,95</a>]. In one study of breast milk samples from 78 Brazilian women with chronic Chagas disease, no infected samples were observed, even though five women had parasitemia at the time of milk collection [<a href="#rid95">95</a>].</p><p class="headingAnchor" id="H4209508624"><span class="h2">Oral transmission</span><span class="headingEndMark"> — </span>Oral transmission of acute <em>T. cruzi</em> infection can occur via ingestion of food or drink contaminated by infected triatomine bugs or their feces [<a href="#rid96">96,97</a>]. Vehicles of oral transmission have included açaí palm fruit, guava juice, and juice prepared from sugarcane [<a href="#rid98">98,99</a>]. However, ingestion of <em>T. cruzi</em> amastigotes via consumption of raw meat is an unlikely mode of transmission [<a href="#rid100">100</a>].</p><p>Acute morbidity in orally transmitted infections appears to be more severe than among patients with vector-borne infection, and case-fatality rates are higher than among patients with vector-borne infection [<a href="#rid96">96</a>].</p><p>Control of oral transmission depends on sustained vector control and improving hygiene in food and beverage preparation.</p><p class="headingAnchor" id="H8"><span class="h2">Blood transfusion</span><span class="headingEndMark"> — </span>Platelet transfusions pose a higher transmission risk than other blood components such as packed red cells [<a href="#rid53">53,101,102</a>]. In one analysis that traced 350 recipients of blood components from infected donors, the risk associated with a platelet unit was estimated to be 13 percent compared with 0 percent for packed red blood cells and frozen plasma/cryoprecipitate [<a href="#rid103">103</a>].</p><p>Transfusion transmission has been reported in the United States [<a href="#rid104">104-107</a>]. At least five of the seven known instances of transfusion transmission involved platelets [<a href="#rid3">3</a>]. No instances of transfusion transmission have been reported since screening of the United States blood supply began in 2007 [<a href="#rid3">3</a>]. (See <a class="local">'Reducing transfusion and transplant transmission'</a> below.)</p><p class="headingAnchor" id="H9"><span class="h2">Organ transplantation</span><span class="headingEndMark"> — </span>Uninfected organ transplant recipients who receive an organ from a donor infected with <em>T. cruzi</em> may develop acute <em>T. cruzi</em> infection. Infection rates after organ transplantation from an infected donor seem to be lower for kidney recipients (0 to 19 percent) than for liver recipients (0 to 29 percent) and heart recipients (75 to 100 percent) [<a href="#rid59">59,108-111</a>]. Transmission via unrelated cord blood transplantation has also been reported [<a href="#rid112">112</a>].</p><p>Following identification of an infected organ donor, close monitoring of the recipient is warranted. (See <a class="local">'Reducing transfusion and transplant transmission'</a> below and  <a class="medical medical_review" href="/z/d/html/114195.html" rel="external">"Chagas disease in the immunosuppressed host", section on 'Monitoring'</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Laboratory accidents</span><span class="headingEndMark"> — </span>Laboratory-acquired <em>T. cruzi</em> infection has rarely occurred via needlestick inoculation or mucous membrane exposure to parasite culture, blood from infected laboratory animals, or infected triatomine fecal material [<a href="#rid113">113</a>].</p><p>Laboratory personnel should use protective equipment to prevent needlesticks and potential contamination of the face, especially the eyes. High-risk accidents comprise needlestick injuries or contamination of the eye or mucous membranes with blood from laboratory animals with known <em>T. cruzi</em> infection [<a href="#rid113">113</a>]. Individuals with high-risk exposures should be monitored by PCR in weekly blood specimens for four weeks and serology at four and eight weeks [<a href="#rid113">113</a>]. Presumptive treatment is not generally recommended. The United States Centers for Disease Control and Prevention provides consultation to health care providers concerning Chagas disease and acts as a reference laboratory for Chagas disease serology and PCR (Division of Parasitic Diseases Public Inquiries line, 404-718-4745; for emergencies after business hours, 770-488-7100; email <a class="__cf_email__" data-cfemail="a5d5c4d7c4d6ccd1c0d6e5c6c1c68bc2cad3" href="/cdn-cgi/l/email-protection">[email protected]</a>).</p><p class="headingAnchor" id="H1933009579"><span class="h2">Risk to travelers</span><span class="headingEndMark"> — </span>The risk to short-term travelers to Latin America is extremely low. Most vector-borne transmission occurs among people living in poor housing conditions and after years of exposure to infected vectors [<a href="#rid114">114,115</a>]. The only documented case of Chagas disease in a United States traveler occurred in the setting of known triatomine exposure in a vulnerable lodging during a three-week trip to Costa Rica [<a href="#rid116">116</a>]. </p><p>Travelers can minimize risk of infection by avoiding poorly constructed accommodations, sleeping under insecticide-treated bed nets with the sides tucked in to prevent entry of vectors, and avoiding consumption of potentially contaminated fruit or cane juices such as those from street vendors [<a href="#rid1">1,117</a>].</p><p class="headingAnchor" id="H3572761064"><span class="h1">PUBLIC HEALTH INTERVENTIONS</span></p><p>Public health interventions to address the burden of Chagas disease can be categorized as primary prevention (prevention of infection), secondary prevention (early detection and treatment to prevent sequelae), or tertiary prevention (medical and surgical management of morbidity to improve survival and quality of life) [<a href="#rid118">118</a>] (<a class="graphic graphic_table graphicRef138385" href="/z/d/graphic/138385.html" rel="external">table 3</a>). Primary prevention of Chagas disease includes vector control and donor screening to prevent transmission via blood components, organs, or tissue. Screening algorithms for control of congenital Chagas disease fall into the category of secondary prevention for the infant and their young siblings and either secondary or tertiary prevention for the mother. Diagnostic testing of patients with heart disease consistent with Chagas cardiomyopathy fits in the category of tertiary prevention. </p><p class="headingAnchor" id="H14"><span class="h2">Vector control</span><span class="headingEndMark"> — </span>The first coordinated national vector control program began in Brazil in 1983 [<a href="#rid119">119</a>]. Between 1991 and 2004, four subregional control programs were established, funded largely by the governments of the countries involved and coordinated by the Pan American Health Organization. The major aims were to control transmission by domestic vectors and to prevent bloodborne <em>T. cruzi</em> transmission. Subsequently, programs to address congenital <em>T. cruzi</em> infection were added in a number of endemic countries [<a href="#rid120">120,121</a>].</p><p>Transmission by domestic vectors has been reduced via residual application of long-lasting insecticides in human dwellings and peridomestic structures. Improving the quality of domestic structures is also a useful control mechanism as this eliminates triatomine bug hiding places and decreases vector colonization and reinfestation of houses [<a href="#rid122">122</a>]. Surveys of sentinel populations are used to monitor the impact of control initiatives; such populations may include children &lt;5 years or young individuals newly recruited to the army [<a href="#rid123">123</a>].</p><p>The Southern Cone Initiative, the first subregional control program to be established, has led to elimination of <em>T. cruzi</em> transmission by domestic <em>T. infestans</em> in Chile (1999), Uruguay (1997), Brazil (2006), and several provinces of Argentina and Paraguay [<a href="#rid124">124,125</a>]. Its success inspired the establishment of several other Chagas control initiatives (<a class="graphic graphic_table graphicRef58263" href="/z/d/graphic/58263.html" rel="external">table 1</a>) [<a href="#rid119">119</a>]. Subsequently, <em>T. cruzi</em> transmission by <em>R. prolixus</em> has been certified as interrupted throughout Central America and southern Mexico [<a href="#rid16">16</a>].</p><p>Despite this progress, foci of vector-borne transmission persist in most endemic countries of Latin America. The success of the Southern Cone Initiative has been challenged by reinfestation from residual vector colonies and the development of insecticide resistance. The Gran Chaco remains a heavily infested ecologic zone shared by Argentina, Bolivia, and Paraguay [<a href="#rid126">126</a>]. Transmission by vectors other than <em>R. prolixus</em> persists in Central America as well as in Mexico. </p><p>Because United States vectors are almost entirely sylvatic, the role of vector control is limited; effective screens, repair of gaps in house exteriors, and clearing brush and woodpiles around houses are recommended, especially in areas with known risk of triatomine home invasion [<a href="#rid127">127</a>].  </p><p class="headingAnchor" id="H1030453935"><span class="h2">Reducing transfusion and transplant transmission</span><span class="headingEndMark"> — </span>In the early 1990s, the prevalence of <em>T. cruzi</em> infection in donated blood units in Latin America ranged from 1 to 60 percent [<a href="#rid128">128</a>]. Serologic screening of blood components for <em>T. cruzi</em> became a component of all of the regional Chagas disease control initiatives and is mandated in all endemic countries (although compliance is variable) [<a href="#rid129">129</a>]. Since this intervention, the risk of transmission via blood transfusion has diminished greatly but has not been eliminated; in such regions, the risk of transmission is estimated to be 1:200,000 units [<a href="#rid102">102,124,129</a>].</p><p>In the United States, voluntary blood bank screening was initiated in 2007 and is estimated to cover 75 to 90 percent of the blood supply [<a href="#rid53">53,104</a>]. A small number of facilities perform screening tests only for donors who report epidemiologic risk factors. However, early studies of risk factor-based screening demonstrated suboptimal effectiveness for this approach [<a href="#rid130">130</a>]. The US Food and Drug Administration recommends screening all donations from individuals not previously screened; repeat screening is not recommended in the absence of a change in exposure history [<a href="#rid41">41,131</a>]. Infected individuals should be counseled not to donate blood. </p><p>Additional issues related to donor screening are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7950.html" rel="external">"Blood donor screening: Medical history", section on 'Chagas disease'</a> and  <a class="medical medical_review" href="/z/d/html/7946.html" rel="external">"Blood donor screening: Laboratory testing", section on 'Chagas disease'</a>.)</p><p>Recipients of an organ or blood product from a donor known to be infected with <em>T. cruzi </em>should be monitored for development of acute <em>T. cruzi</em> infection; this is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/114195.html" rel="external">"Chagas disease in the immunosuppressed host", section on 'Monitoring'</a> and  <a class="medical medical_review" href="/z/d/html/114181.html" rel="external">"Chagas disease: Acute and congenital Trypanosoma cruzi infection", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H4055164388"><span class="h1">SCREENING FOR CHAGAS DISEASE IN NONENDEMIC CLINICAL AND COMMUNITY SETTINGS</span></p><p class="headingAnchor" id="H1894386518"><span class="h2">Summary of screening recommendations</span><span class="headingEndMark"> — </span>Selection of populations who can be expected to benefit from screening for Chagas disease is based on epidemiologic risk factors, risk of transmission to others, and risk of morbidity and mortality from reactivation. Screening test modalities include serology, microscopy, and molecular testing with polymerase chain reaction (PCR); selection of appropriate testing modality is determined by the individual’s age and immune status, and the suspected phase of <em>T. cruzi</em> infection (<a class="graphic graphic_table graphicRef138385" href="/z/d/graphic/138385.html" rel="external">table 3</a>). </p><p class="bulletIndent1"><span class="glyph">●</span>We suggest screening with a single, highly sensitive immunoglobulin (Ig)G serologic test for individuals who are nine months of age or older and meet one or more of the following criteria:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Persons who were born in or lived for at least six months in an endemic country of Latin America (high priority should be given to screening females of reproductive age, either prenatally or during routine care) </p><p class="bulletIndent2"><span class="glyph">•</span>Persons born to a mother with confirmed <em>T. cruzi</em> infection </p><p class="bulletIndent2"><span class="glyph">•</span>Persons with evidence of a bite or other exposure to a triatomine bug in Latin America or regions of United States with known enzootic cycles</p><p class="bulletIndent2"><span class="glyph">•</span>Living organ donors with any of the above epidemiologic risk factors </p><p class="bulletIndent2"><span class="glyph">•</span>Individuals who have any of the epidemiologic risk factors above and are transplant candidates/recipients or have HIV </p><p></p><p class="bulletIndent1">Individuals with positive results by the screening test should undergo confirmatory testing with one or more additional distinct serologic assays. Confirmed diagnosis requires positive results by at least two distinct tests, preferably based on different antigens. Those with a confirmed diagnosis should undergo evaluation and potentially treatment for chronic Chagas disease. (See  <a class="medical medical_review" href="/z/d/html/114192.html" rel="external">"Chagas disease: Chronic Trypanosoma cruzi infection", section on 'Diagnosis'</a>.)<strong> </strong></p><p></p><p class="bulletIndent1">Individuals with profound immunosuppression may have false negative serology; in such cases, molecular testing may be warranted when the suspicion for Chagas disease remains high despite a negative screening IgG assay.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest screening infants born to mothers with <em>T. cruzi</em> infection with PCR (plus microscopy if available) twice in the first three months of life, followed by IgG serology at nine months or later (<a class="graphic graphic_algorithm graphicRef114689" href="/z/d/graphic/114689.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/114181.html" rel="external">"Chagas disease: Acute and congenital Trypanosoma cruzi infection", section on 'Diagnosis'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest serial monitoring with PCR for the following groups:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Recipient of an organ or tissue from a donor infected with <em>T. cruzi</em> (See  <a class="medical medical_review" href="/z/d/html/114195.html" rel="external">"Chagas disease in the immunosuppressed host", section on 'Monitoring'</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Transplant recipients with pre-existing chronic <em>T. cruzi</em> infection at risk for reactivation (See  <a class="medical medical_review" href="/z/d/html/114195.html" rel="external">"Chagas disease in the immunosuppressed host", section on 'Monitoring'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest that patients with epidemiologic risk factors and cardiac findings (arrhythmias, conduction abnormalities, congestive heart failure and/or reduced ejection fraction, regional wall motion abnormalities [particularly basal inferolateral or apical aneurysm], and thromboembolic phenomenon) suggestive of Chagas cardiomyopathy and/or gastrointestinal findings (megaesophagus, megacolon) suggestive of digestive Chagas disease undergo diagnostic testing with two distinct serologic assays. (See  <a class="medical medical_review" href="/z/d/html/4955.html" rel="external">"Chronic Chagas cardiomyopathy: Clinical manifestations and diagnosis", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/5700.html" rel="external">"Chagas gastrointestinal disease", section on 'Diagnosis'</a>.)</p><p></p><p class="headingAnchor" id="H3653998954"><span class="h2">Rationale for screening</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale for screening asymptomatic persons with epidemiologic risk </strong>– We suggest serologic screening in primary care settings targeted to those with epidemiologic risk [<a href="#rid132">132</a>]. Because the majority of infected persons are asymptomatic for many years, if not throughout their lives, the only way to detect infection early is to screen populations at risk, either in community settings [<a href="#rid47">47,133</a>] or through primary care providers [<a href="#rid134">134</a>]. The expected prevalence of infection depends on the age groups screened and predominant source countries. The prevalence of Chagas disease in the United States among those born in Latin America is estimated to be 1 to 3 percent [<a href="#rid47">47,133,135</a>]. (See <a class="local">'Geographic distribution'</a> above.)</p><p></p><p class="bulletIndent1">The major epidemiologic risk factor for <em>T. cruzi</em> infection in the United States and other nonendemic areas is prolonged exposure in endemic countries of Latin America [<a href="#rid3">3</a>]. Other risk factors include being born to a woman with prolonged exposure and/or birth in an endemic country and evidence of a bite or other exposure to a triatomine bug in Latin America or United States regions with known enzootic cycles. If a person’s mother is known to have epidemiologic risk factors but her infection status cannot be determined, it is reasonable to screen that person as well.  </p><p></p><p class="bulletIndent1">As reviewed above, risk within endemic countries is extremely heterogeneous, with essentially no transmission risk in most urban centers. In rural areas, transmission risk varies greatly with triatomine species, density and behavior, house vulnerability to infestation, and presence of nonhuman animal reservoirs. However, given the lifelong nature of the infection and lack of detailed geographic risk data, the most prudent approach is to assume anyone born in or who has spent prolonged time in an endemic country may be at risk and should be screened at least once. Many publications use a cutoff of six months to define an exposure period warranting testing, although data informing a specific exposure period are minimal [<a href="#rid132">132</a>]. (See <a class="local">'Geographic distribution'</a> above.)</p><p></p><p class="bulletIndent1">All individuals confirmed to have Chagas disease should undergo evaluation for cardiac or gastrointestinal involvement [<a href="#rid136">136</a>]. As an example, in a study of 302 women (median age 27 years) in Bolivia infected with <em>T. cruzi</em>, 28 (9.3 percent) had electrocardiography changes characteristic of Chagas cardiomyopathy [<a href="#rid85">85</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening females of childbearing age and infants</strong> – Prenatal screening and screening for females who may become pregnant in the future is suggested for those with epidemiologic risk factors in order to prevent and treat congenital Chagas disease [<a href="#rid132">132</a>]. Treatment of infection prior to pregnancy decreases the risk of subsequent congenital transmission by an estimated 95 percent [<a href="#rid86">86,92</a>]. As with all other patients, females diagnosed with infection should undergo evaluation for cardiac or gastrointestinal involvement. Identification of <em>T. cruzi</em> infection in a female should prompt testing of all biological children; a mother with one infected infant may have a higher risk for transmission of infection to her other children [<a href="#rid85">85,137,138</a>].  </p><p></p><p class="bulletIndent1">Congenital Chagas disease screening requires a multistep algorithm: (1) serologic screening and confirmation of <em>T. cruzi</em> infection in pregnant females (and females planning pregnancy), followed by (2) testing of infants of infected mothers with microscopy and/or molecular methods at birth and in the early months of life, and (3) for infants with negative screening earlier in infancy, IgG serology at nine months or later [<a href="#rid137">137</a>] (<a class="graphic graphic_algorithm graphicRef114689" href="/z/d/graphic/114689.html" rel="external">algorithm 1</a>). The multistep process is necessary to identify congenital Chagas disease since one step testing is not sensitive enough to detect all cases early in life. Microscopy and PCR have a sensitivity of ≤50 percent and 70 to 75 percent in a single specimen, respectively [<a href="#rid139">139</a>]. An additional infant specimen tested at 30 to 90 days increases the likelihood of early detection. Follow-up with IgG serology at 9 to 12 months of age (when maternal IgG has cleared) is necessary to rule out infection in the infant.</p><p></p><p class="bulletIndent1">Screening females of child-bearing age at high risk for Chagas disease in the United States has been shown to be cost effective. A study that compared the costs of testing and treating mothers and infants with the lifetime societal costs in the absence of testing found screening of high risk females to be cost-effective when maternal prevalence of Chagas disease is greater than 0.06 percent [<a href="#rid140">140</a>]. Among pregnant Latin American-born females in one Houston hospital, the prevalence of Chagas disease was estimated to be 0.3 percent [<a href="#rid141">141,142</a>]. </p><p></p><p class="bulletIndent1">Countries with a high burden of Chagas disease, such as Bolivia and Argentina, have large-scale congenital Chagas disease screening programs [<a href="#rid79">79,143-146</a>]. The weakest aspects of current screening programs are the low sensitivity of microscopy, lack of availability of reliable molecular laboratories in endemic zones, and low rates of follow-up (&lt;20 percent) at the 9 to 12 month visit; at least half of congenital infections are likely missed by current screening [<a href="#rid139">139,147,148</a>]. (See  <a class="medical medical_review" href="/z/d/html/114181.html" rel="external">"Chagas disease: Acute and congenital Trypanosoma cruzi infection", section on 'Congenital Chagas disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening persons with epidemiologic risk who are or may become immunosuppressed</strong> – Screening is suggested for individuals with epidemiologic risk for Chagas disease who are transplant candidates, are transplant recipients, or have HIV.</p><p></p><p class="bulletIndent1"><em>T. cruzi</em> infection in the immunosuppressed patient can result in life-threatening reactivation disease. Patients receiving a kidney, liver, or heart transplant from an infected donor have up to 19, 29, and 100 percent risk, respectively, of developing <em>T. cruzi</em> infection [<a href="#rid59">59,62,108-111</a>]. Molecular monitoring can detect infection prior to the onset of symptoms, allowing for prompt antitrypanosomal therapy. </p><p></p><p class="bulletIndent1">For transplant candidates who have chronic Chagas disease prior to transplantation, risk of reactivation after transplantation is approximately 20 percent [<a href="#rid108">108</a>]. </p><p></p><p class="bulletIndent1">Immunosuppression may cause falsely negative serology [<a href="#rid149">149</a>]. If suspicion for Chagas disease remains high despite negative serology, molecular testing for Chagas disease with PCR may be warranted. (See  <a class="medical medical_review" href="/z/d/html/114195.html" rel="external">"Chagas disease in the immunosuppressed host"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic testing in persons with epidemiologic risk and evidence of existing cardiomyopathy or gastrointestinal Chagas disease </strong>– Diagnostic testing is suggested for patients with epidemiologic risk and cardiac or gastrointestinal findings consistent with Chagas disease. Five to nearly 20 percent of Latin American-born patients with nonischemic cardiomyopathy have Chagas disease [<a href="#rid48">48-51</a>]. Even though antitrypanosomal therapy does not significantly slow progression of established cardiomyopathy [<a href="#rid150">150</a>], knowledge of the etiology remains important for cardiac medical management and is crucial prior to heart transplantation to enable prospective monitoring for reactivation when immunosuppression occurs [<a href="#rid136">136,151</a>]. (See  <a class="medical medical_review" href="/z/d/html/4955.html" rel="external">"Chronic Chagas cardiomyopathy: Clinical manifestations and diagnosis", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/5700.html" rel="external">"Chagas gastrointestinal disease", section on 'Diagnosis'</a>.)   </p><p></p><p class="headingAnchor" id="H3083700441"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113058.html" rel="external">"Society guideline links: Chagas disease"</a>.)</p><p class="headingAnchor" id="H1998545590"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/97518.html" rel="external">"Patient education: Chagas disease (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1618493929"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction</strong> − Chagas disease is caused by infection with the protozoan parasite <em>Trypanosoma cruzi</em>, principally transmitted by triatomine bugs endemic to Latin America and the southern regions of United States. (See <a class="local">'Introduction'</a> above and <a class="local">'Geographic distribution'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – An estimated 6 million people are infected with Chagas disease, mostly due to vector-borne transmission in poor housing conditions in endemic regions of Latin America. The epidemiology of the disease is changing due to successful reduction of transmission in endemic areas as well as migration of individuals within and outside of endemic areas. Hundreds of thousands of infected individuals live in cities across Latin America and in the United States, Spain, and other European countries. (See <a class="local">'Epidemiology and vectorial transmission'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vector transmission and life cycle </strong>− The infective trypomastigote form of the <em>T. cruzi</em> parasite is present in large numbers in the feces of infected triatomine bugs. During or immediately after a blood meal, the triatomine bug defecates on the skin of the host, allowing the organism to enter through the bite wound or via intact conjunctiva or mucous membranes. The risk of infection in the setting of short-term exposure is low; mathematical models estimate that, on average, 900 to 4000 contacts with infected vectors are needed to result in infection. (See <a class="local">'Vector transmission and life cycle'</a> above and <a class="local">'Risk to travelers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other modes of</strong> <strong>transmission</strong> – In addition to vector transmission, Chagas disease transmission can also occur vertically from mother to fetus, via breastfeeding, via transfusion of infected blood components, via organ transplantation from an infected donor, via ingestion of contaminated food or drink, or via laboratory exposure. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vector control</strong> − Transmission by domestic vectors has been reduced via residual application of long-lasting insecticides in human dwellings and peridomestic structures. Despite this progress, foci of vector-borne transmission persist in most endemic countries of Latin America. (See <a class="local">'Vector control'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood transfusion screening</strong> − Serologic screening of blood components for <em>T. cruzi</em> became a component of all of the regional Chagas disease control initiatives and is mandated in all endemic countries (although compliance is variable). Since this intervention, the risk of transmission via blood transfusion has diminished greatly but has not been eliminated; in such regions, the risk of transmission is estimated to be 1:200,000 units. The US Food and Drug Administration recommends screening all donations from individuals not previously screened. (See <a class="local">'Reducing transfusion and transplant transmission'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening recommendations</strong> <strong>in nonendemic clinical and community settings</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest screening with a single, highly sensitive immunoglobulin (Ig)G serologic test for individuals who are nine months of age or older and meet one of the following criteria (<a class="graphic graphic_table graphicRef138385" href="/z/d/graphic/138385.html" rel="external">table 3</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Persons who were born in or lived for at least six months in an endemic country of Latin America (high priority should be given to screening females of reproductive age, either prenatally or during routine care). </p><p class="bulletIndent3"><span class="glyph">-</span>Persons born to a mother with confirmed <em>T. cruzi</em> infection </p><p class="bulletIndent3"><span class="glyph">-</span>Persons with evidence of a bite or other exposure to a triatomine bug in Latin America or regions of United States with known enzootic cycles </p><p class="bulletIndent3"><span class="glyph">-</span>Living organ donors with any of the above epidemiologic risk factors </p><p class="bulletIndent3"><span class="glyph">-</span>Individuals who have any of the epidemiology risk factors above and are transplant candidates/recipients or have HIV. (See <a class="local">'Summary of screening recommendations'</a> above and <a class="local">'Rationale for screening'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For infants born to mothers with <em>T. cruzi</em> infection, we perform screening with PCR (plus microscopy if available) twice in the first three months of life, followed by IgG serology at nine months or later (<a class="graphic graphic_algorithm graphicRef114689" href="/z/d/graphic/114689.html" rel="external">algorithm 1</a>). (See <a class="local">'Rationale for screening'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We perform serial surveillance with PCR for recipients of an organ or tissue from a donor infected with <em>T. cruzi</em> and transplant recipients with pre-existing chronic <em>T. cruzi</em> infection at risk for reactivation. (See <a class="local">'Rationale for screening'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with epidemiologic risk factors and findings suggestive of Chagas cardiomyopathy and/or digestive Chagas disease, we perform diagnostic testing with two distinct serologic assays. (See <a class="local">'Rationale for screening'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Pérez-Molina JA, Molina I. Chagas disease. Lancet 2018; 391:82.</a></li><li><a class="nounderline abstract_t">Bern C. Chagas' Disease. N Engl J Med 2015; 373:456.</a></li><li><a class="nounderline abstract_t">Bern C, Messenger LA, Whitman JD, Maguire JH. Chagas Disease in the United States: a Public Health Approach. Clin Microbiol Rev 2019; 33.</a></li><li class="breakAll">World Health Organization. Health Statistics and information systems: Estimates for 2000-2012. http://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html (Accessed on September 21, 2016).</li><li><a class="nounderline abstract_t">Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet 2010; 375:1388.</a></li><li><a class="nounderline abstract_t">Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Wkly Epidemiol Rec 2015; 90:33.</a></li><li><a class="nounderline abstract_t">Lent H, Wygodzinsky P. Revision of the Triatominae (Hemiptera, Reduviidae), and their significance as vectors of Chagas' disease. Bull Am Mus Nat Hist 1979; 63:123.</a></li><li class="breakAll">WHO Expert Committee. Control of Chagas Disease. Brasilia, Brazil: World Health Organization, 2002:1-109.</li><li><a class="nounderline abstract_t">Coura JR, Junqueira AC, Fernandes O, et al. Emerging Chagas disease in Amazonian Brazil. Trends Parasitol 2002; 18:171.</a></li><li><a class="nounderline abstract_t">Cohen JE, Gürtler RE. Modeling household transmission of American trypanosomiasis. Science 2001; 293:694.</a></li><li><a class="nounderline abstract_t">Gurtler RE, Cohen JE, Cecere MC, et al. Influence of humans and domestic animals on the household prevalence of Trypanosoma cruzi in Triatoma infestans populations in northwest Argentina. Am J Trop Med Hyg 1998; 58:748.</a></li><li><a class="nounderline abstract_t">HERRER A. CHAGAS' DISEASE IN PERU. I. THE EPIDEMIOLOGICAL IMPORTANCE OF THE GUINEA PIG. Trop Geogr Med 1964; 16:146.</a></li><li><a class="nounderline abstract_t">Miles MA, Feliciangeli MD, de Arias AR. American trypanosomiasis (Chagas' disease) and the role of molecular epidemiology in guiding control strategies. BMJ 2003; 326:1444.</a></li><li><a class="nounderline abstract_t">Schofield CJ, Galvão C. Classification, evolution, and species groups within the Triatominae. Acta Trop 2009; 110:88.</a></li><li><a class="nounderline abstract_t">Miles MA, Llewellyn MS, Lewis MD, et al. The molecular epidemiology and phylogeography of Trypanosoma cruzi and parallel research on Leishmania: looking back and to the future. Parasitology 2009; 136:1509.</a></li><li><a class="nounderline abstract_t">Hashimoto K, Schofield CJ. Elimination of Rhodnius prolixus in Central America. Parasit Vectors 2012; 5:45.</a></li><li class="breakAll">Gorla DE, Noireau F. Geographic Distribution of Triatominae Vectors in America. In: American Trypanosomiasis Chagas Disease: One Hundred Years of Research, Telleria J, Tibayrenc M (Eds), Elsevier, London 2010. p.209.</li><li><a class="nounderline abstract_t">Levy MZ, Bowman NM, Kawai V, et al. Periurban Trypanosoma cruzi-infected Triatoma infestans, Arequipa, Peru. Emerg Infect Dis 2006; 12:1345.</a></li><li><a class="nounderline abstract_t">Mott KE, Muniz TM, Lehman JS Jr, et al. House construction, triatomine distribution, and household distribution of seroreactivity to Trypanosoma cruzi in a rural community in northeast Brazil. Am J Trop Med Hyg 1978; 27:1116.</a></li><li><a class="nounderline abstract_t">Grijalva MJ, Escalante L, Paredes RA, et al. Seroprevalence and risk factors for Trypanosoma cruzi infection in the Amazon region of Ecuador. Am J Trop Med Hyg 2003; 69:380.</a></li><li><a class="nounderline abstract_t">Pless M, Juranek D, Kozarsky P, et al. The epidemiology of Chagas' disease in a hyperendemic area of Cochabamba, Bolivia: a clinical study including electrocardiography, seroreactivity to Trypanosoma cruzi, xenodiagnosis, and domiciliary triatomine distribution. Am J Trop Med Hyg 1992; 47:539.</a></li><li><a class="nounderline abstract_t">Feliciangeli MD, Campbell-Lendrum D, Martinez C, et al. Chagas disease control in Venezuela: lessons for the Andean region and beyond. Trends Parasitol 2003; 19:44.</a></li><li><a class="nounderline abstract_t">Samuels AM, Clark EH, Galdos-Cardenas G, et al. Epidemiology of and impact of insecticide spraying on Chagas disease in communities in the Bolivian Chaco. PLoS Negl Trop Dis 2013; 7:e2358.</a></li><li><a class="nounderline abstract_t">Mott KE, Lehman JS Jr, hoff R, et al. The epidemiology and household distribution of seroreactivity to Trypanosoma cruzi in a rural community in northeast Brazil. Am J Trop Med Hyg 1976; 25:552.</a></li><li class="breakAll">Lopez-Velez R, Norman FF, Bern C. American Trypanosomiasis (Chagas Disease). In: Hunter's Tropical Medicine and Emerging Infectious Desease, 9th ed, Magill AJ, Ryan ET, Solomon T, Hill DR (Eds), Saunders, Philadelphia 2013. p.725.</li><li><a class="nounderline abstract_t">Maguire JH, Hoff R, Sherlock I, et al. Cardiac morbidity and mortality due to Chagas' disease: prospective electrocardiographic study of a Brazilian community. Circulation 1987; 75:1140.</a></li><li><a class="nounderline abstract_t">Fernandez AB, Nunes MC, Clark EH, et al. Electrocardiographic and echocardiographic abnormalities in Chagas disease: findings in residents of rural Bolivian communities hyperendemic for Chagas disease. Glob Heart 2015; 10:159.</a></li><li><a class="nounderline abstract_t">Beard CB, Pye G, Steurer FJ, et al. Chagas disease in a domestic transmission cycle, southern Texas, USA. Emerg Infect Dis 2003; 9:103.</a></li><li><a class="nounderline abstract_t">Kjos SA, Snowden KF, Craig TM, et al. Distribution and characterization of canine Chagas disease in Texas. Vet Parasitol 2008; 152:249.</a></li><li><a class="nounderline abstract_t">Yabsley MJ, Noblet GP. Seroprevalence of Trypanosoma cruzi in raccoons from South Carolina and Georgia. J Wildl Dis 2002; 38:75.</a></li><li><a class="nounderline abstract_t">Reisenman CE, Lawrence G, Guerenstein PG, et al. Infection of kissing bugs with Trypanosoma cruzi, Tucson, Arizona, USA. Emerg Infect Dis 2010; 16:400.</a></li><li><a class="nounderline abstract_t">Dorn PL, Perniciaro L, Yabsley MJ, et al. Autochthonous transmission of Trypanosoma cruzi, Louisiana. Emerg Infect Dis 2007; 13:605.</a></li><li><a class="nounderline abstract_t">Navin TR, Roberto RR, Juranek DD, et al. Human and sylvatic Trypanosoma cruzi infection in California. Am J Public Health 1985; 75:366.</a></li><li><a class="nounderline abstract_t">Ochs DE, Hnilica VS, Moser DR, et al. Postmortem diagnosis of autochthonous acute chagasic myocarditis by polymerase chain reaction amplification of a species-specific DNA sequence of Trypanosoma cruzi. Am J Trop Med Hyg 1996; 54:526.</a></li><li><a class="nounderline abstract_t">Schiffler RJ, Mansur GP, Navin TR, Limpakarnjanarat K. Indigenous Chagas' disease (American trypanosomiasis) in California. JAMA 1984; 251:2983.</a></li><li><a class="nounderline abstract_t">WOODY NC, WOODY HB. American trypanosomiasis (Chagas' disease); first indigenous case in the United States. J Am Med Assoc 1955; 159:676.</a></li><li><a class="nounderline abstract_t">Kjos SA, Gillespie JJ, Olson JK, Snowden KF. Detection of Blastocrithidia spp. (Kinetoplastida: Trypanosomatidae) in Chagas disease vectors from Texas, USA. Vector Borne Zoonotic Dis 2009; 9:213.</a></li><li><a class="nounderline abstract_t">Garcia MN, Aguilar D, Gorchakov R, et al. Evidence of autochthonous Chagas disease in southeastern Texas. Am J Trop Med Hyg 2015; 92:325.</a></li><li><a class="nounderline abstract_t">Turabelidze G, Vasudevan A, Rojas-Moreno C, et al. Autochthonous Chagas Disease - Missouri, 2018. MMWR Morb Mortal Wkly Rep 2020; 69:193.</a></li><li><a class="nounderline abstract_t">Klotz SA, Dorn PL, Klotz JH, et al. Feeding behavior of triatomines from the southwestern United States: an update on potential risk for transmission of Chagas disease. Acta Trop 2009; 111:114.</a></li><li><a class="nounderline abstract_t">Dodd RY, Groves JA, Townsend RL, et al. Impact of one-time testing for Trypanosoma cruzi antibodies among blood donors in the United States. Transfusion 2019; 59:1016.</a></li><li><a class="nounderline abstract_t">Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis 2009; 49:e52.</a></li><li><a class="nounderline abstract_t">Gascon J, Bern C, Pinazo MJ. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop 2010; 115:22.</a></li><li><a class="nounderline abstract_t">Bern C, Verastegui M, Gilman RH, et al. Congenital Trypanosoma cruzi transmission in Santa Cruz, Bolivia. Clin Infect Dis 2009; 49:1667.</a></li><li><a class="nounderline abstract_t">Hidron AI, Gilman RH, Justiniano J, et al. Chagas cardiomyopathy in the context of the chronic disease transition. PLoS Negl Trop Dis 2010; 4:e688.</a></li><li><a class="nounderline abstract_t">Bennett C, Straily A, Haselow D, et al. Chagas Disease Surveillance Activities - Seven States, 2017. MMWR Morb Mortal Wkly Rep 2018; 67:738.</a></li><li><a class="nounderline abstract_t">Meymandi SK, Forsyth CJ, Soverow J, et al. Prevalence of Chagas Disease in the Latin American-born Population of Los Angeles. Clin Infect Dis 2017; 64:1182.</a></li><li><a class="nounderline abstract_t">Kapelusznik L, Varela D, Montgomery SP, et al. Chagas disease in Latin American immigrants with dilated cardiomyopathy in New York City. Clin Infect Dis 2013; 57:e7.</a></li><li><a class="nounderline abstract_t">Traina MI, Sanchez DR, Hernandez S, et al. Prevalence and Impact of Chagas Disease Among Latin American Immigrants With Nonischemic Cardiomyopathy in Los Angeles, California. Circ Heart Fail 2015; 8:938.</a></li><li><a class="nounderline abstract_t">Traina MI, Hernandez S, Sanchez DR, et al. Prevalence of Chagas Disease in a U.S. Population of Latin American Immigrants with Conduction Abnormalities on Electrocardiogram. PLoS Negl Trop Dis 2017; 11:e0005244.</a></li><li><a class="nounderline abstract_t">Park S, Sanchez DR, Traina MI, et al. The Prevalence of Chagas Disease Among Latin American Immigrants with Pacemakers in Los Angeles, California. Am J Trop Med Hyg 2017; 96:1139.</a></li><li><a class="nounderline abstract_t">Requena-Méndez A, Aldasoro E, de Lazzari E, et al. Prevalence of Chagas disease in Latin-American migrants living in Europe: a systematic review and meta-analysis. PLoS Negl Trop Dis 2015; 9:e0003540.</a></li><li><a class="nounderline abstract_t">Bern C, Montgomery SP, Katz L, et al. Chagas disease and the US blood supply. Curr Opin Infect Dis 2008; 21:476.</a></li><li><a class="nounderline abstract_t">Cantey PT, Stramer SL, Townsend RL, et al. The United States Trypanosoma cruzi Infection Study: evidence for vector-borne transmission of the parasite that causes Chagas disease among United States blood donors. Transfusion 2012; 52:1922.</a></li><li><a class="nounderline abstract_t">Jackson Y, Myers C, Diana A, et al. Congenital transmission of Chagas disease in Latin American immigrants in Switzerland. Emerg Infect Dis 2009; 15:601.</a></li><li><a class="nounderline abstract_t">Muñoz J, Portús M, Corachan M, et al. Congenital Trypanosoma cruzi infection in a non-endemic area. Trans R Soc Trop Med Hyg 2007; 101:1161.</a></li><li><a class="nounderline abstract_t">Bern C, Kjos S, Yabsley MJ, Montgomery SP. Trypanosoma cruzi and Chagas' Disease in the United States. Clin Microbiol Rev 2011; 24:655.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Congenital transmission of Chagas disease - Virginia, 2010. MMWR Morb Mortal Wkly Rep 2012; 61:477.</a></li><li><a class="nounderline abstract_t">Huprikar S, Bosserman E, Patel G, et al. Donor-derived Trypanosoma cruzi infection in solid organ recipients in the United States, 2001-2011. Am J Transplant 2013; 13:2418.</a></li><li><a class="nounderline abstract_t">Almeida EA, Ramos Júnior AN, Correia D, Shikanai-Yasuda MA. Co-infection Trypanosoma cruzi/HIV: systematic review (1980-2010). Rev Soc Bras Med Trop 2011; 44:762.</a></li><li><a class="nounderline abstract_t">Campo M, Phung MK, Ahmed R, et al. A woman with HIV infection, brain abscesses, and eosinophilia. Clin Infect Dis 2010; 50:239.</a></li><li><a class="nounderline abstract_t">Bern C. Chagas disease in the immunosuppressed host. Curr Opin Infect Dis 2012; 25:450.</a></li><li><a class="nounderline abstract_t">Cordova E, Boschi A, Ambrosioni J, et al. Reactivation of Chagas disease with central nervous system involvement in HIV-infected patients in Argentina, 1992-2007. Int J Infect Dis 2008; 12:587.</a></li><li><a class="nounderline abstract_t">Castro-Sesquen YE, Gilman RH, Mejia C, et al. Use of a Chagas Urine Nanoparticle Test (Chunap) to Correlate with Parasitemia Levels in T. cruzi/HIV Co-infected Patients. PLoS Negl Trop Dis 2016; 10:e0004407.</a></li><li><a class="nounderline abstract_t">Gürtler RE. Sustainability of vector control strategies in the Gran Chaco Region: current challenges and possible approaches. Mem Inst Oswaldo Cruz 2009; 104 Suppl 1:52.</a></li><li><a class="nounderline abstract_t">Chippaux JP, Postigo JR, Santalla JA, et al. Epidemiological evaluation of Chagas disease in a rural area of southern Bolivia. Trans R Soc Trop Med Hyg 2008; 102:578.</a></li><li><a class="nounderline abstract_t">Miles MA, Cedillos RA, Póvoa MM, et al. Do radically dissimilar Trypanosoma cruzi strains (zymodemes) cause Venezuelan and Brazilian forms of Chagas' disease? Lancet 1981; 1:1338.</a></li><li><a class="nounderline abstract_t">Zingales B, Miles MA, Campbell DA, et al. The revised Trypanosoma cruzi subspecific nomenclature: rationale, epidemiological relevance and research applications. Infect Genet Evol 2012; 12:240.</a></li><li><a class="nounderline abstract_t">Zingales B. Trypanosoma cruzi genetic diversity: Something new for something known about Chagas disease manifestations, serodiagnosis and drug sensitivity. Acta Trop 2018; 184:38.</a></li><li><a class="nounderline abstract_t">Ramírez JD, Guhl F, Rendón LM, et al. Chagas cardiomyopathy manifestations and Trypanosoma cruzi genotypes circulating in chronic Chagasic patients. PLoS Negl Trop Dis 2010; 4:e899.</a></li><li><a class="nounderline abstract_t">Carrasco HJ, Segovia M, Llewellyn MS, et al. Geographical distribution of Trypanosoma cruzi genotypes in Venezuela. PLoS Negl Trop Dis 2012; 6:e1707.</a></li><li><a class="nounderline abstract_t">Martínez I, Nogueda B, Martínez-Hernández F, Espinoza B. Microsatellite and mini-exon analysis of Mexican human DTU I Trypanosoma cruzi strains and their susceptibility to nifurtimox and benznidazole. Vector Borne Zoonotic Dis 2013; 13:181.</a></li><li><a class="nounderline abstract_t">Messenger LA, Miles MA, Bern C. Between a bug and a hard place: Trypanosoma cruzi genetic diversity and the clinical outcomes of Chagas disease. Expert Rev Anti Infect Ther 2015; 13:995.</a></li><li><a class="nounderline abstract_t">Bhattacharyya T, Falconar AK, Luquetti AO, et al. Development of peptide-based lineage-specific serology for chronic Chagas disease: geographical and clinical distribution of epitope recognition. PLoS Negl Trop Dis 2014; 8:e2892.</a></li><li><a class="nounderline abstract_t">Bhattacharyya T, Messenger LA, Bern C, et al. Severity of Chagasic Cardiomyopathy Is Associated With Response to a Novel Rapid Diagnostic Test for Trypanosoma cruzi TcII/V/VI. Clin Infect Dis 2018; 67:519.</a></li><li><a class="nounderline abstract_t">Murphy N, Rooney B, Bhattacharyya T, et al. Glycosylation of Trypanosoma cruzi TcI antigen reveals recognition by chagasic sera. Sci Rep 2020; 10:16395.</a></li><li><a class="nounderline abstract_t">Schenone H, Gaggero M, Sapunar J, et al. Congenital Chagas disease of second generation in Santiago, Chile. Report of two cases. Rev Inst Med Trop Sao Paulo 2001; 43:231.</a></li><li><a class="nounderline abstract_t">Torrico F, Alonso-Vega C, Suarez E, et al. Maternal Trypanosoma cruzi infection, pregnancy outcome, morbidity, and mortality of congenitally infected and non-infected newborns in Bolivia. Am J Trop Med Hyg 2004; 70:201.</a></li><li><a class="nounderline abstract_t">Sosa-Estani S. [Congenital transmission of Trypanosoma cruzi infection in Argentina]. Rev Soc Bras Med Trop 2005; 38 Suppl 2:29.</a></li><li class="breakAll">Schijman AG. Congenital Chagas Disease. In: Congenital and Other Related Infectious Diseases of the Newborn, Mushahwar IK (Ed), Elsevier, Amsterdam, Netherlands 2006. Vol 13, p.223.</li><li><a class="nounderline abstract_t">Azogue E, Darras C. [Prospective study of Chagas disease in newborn children with placental infection caused by Trypanosoma cruzi (Santa Cruz-Bolivia)]. Rev Soc Bras Med Trop 1991; 24:105.</a></li><li><a class="nounderline abstract_t">Basombrío MA, Nasser J, Segura MA, et al. [The transmission de Chagas disease in Salta and the detection of congenital cases]. Medicina (B Aires) 1999; 59 Suppl 2:143.</a></li><li><a class="nounderline abstract_t">Murcia L, Carrilero B, Munoz-Davila MJ, et al. Risk factors and primary prevention of congenital Chagas disease in a nonendemic country. Clin Infect Dis 2013; 56:496.</a></li><li><a class="nounderline abstract_t">Howard EJ, Xiong X, Carlier Y, et al. Frequency of the congenital transmission of Trypanosoma cruzi: a systematic review and meta-analysis. BJOG 2014; 121:22.</a></li><li><a class="nounderline abstract_t">Kaplinski M, Jois M, Galdos-Cardenas G, et al. Sustained Domestic Vector Exposure Is Associated With Increased Chagas Cardiomyopathy Risk but Decreased Parasitemia and Congenital Transmission Risk Among Young Women in Bolivia. Clin Infect Dis 2015; 61:918.</a></li><li><a class="nounderline abstract_t">Murcia L, Simón M, Carrilero B, et al. Treatment of Infected Women of Childbearing Age Prevents Congenital Trypanosoma cruzi Infection by Eliminating the Parasitemia Detected by PCR. J Infect Dis 2017; 215:1452.</a></li><li><a class="nounderline abstract_t">Bittencourt AL. Possible risk factors for vertical transmission of Chagas' disease. Rev Inst Med Trop Sao Paulo 1992; 34:403.</a></li><li><a class="nounderline abstract_t">Freilij H, Altcheh J. Congenital Chagas' disease: diagnostic and clinical aspects. Clin Infect Dis 1995; 21:551.</a></li><li><a class="nounderline abstract_t">Andrade SG. The influence of the strain of Trypanosoma cruzi in placental infections in mice. Trans R Soc Trop Med Hyg 1982; 76:123.</a></li><li><a class="nounderline abstract_t">Virreira M, Truyens C, Alonso-Vega C, et al. Comparison of Trypanosoma cruzi lineages and levels of parasitic DNA in infected mothers and their newborns. Am J Trop Med Hyg 2007; 77:102.</a></li><li><a class="nounderline abstract_t">Sosa-Estani S, Cura E, Velazquez E, et al. Etiological treatment of young women infected with Trypanosoma cruzi, and prevention of congenital transmission. Rev Soc Bras Med Trop 2009; 42:484.</a></li><li><a class="nounderline abstract_t">Fabbro DL, Danesi E, Olivera V, et al. Trypanocide treatment of women infected with Trypanosoma cruzi and its effect on preventing congenital Chagas. PLoS Negl Trop Dis 2014; 8:e3312.</a></li><li><a class="nounderline abstract_t">Murillo J, Bofill LM, Bolivar H, et al. Congenital Chagas' disease transmission in the United States: Diagnosis in adulthood. IDCases 2016; 5:72.</a></li><li><a class="nounderline abstract_t">Norman FF, López-Vélez R. Chagas disease and breast-feeding. Emerg Infect Dis 2013; 19:1561.</a></li><li><a class="nounderline abstract_t">Bittencourt AL, Sadigursky M, Da Silva AA, et al. Evaluation of Chagas' disease transmission through breast-feeding. Mem Inst Oswaldo Cruz 1988; 83:37.</a></li><li><a class="nounderline abstract_t">Pereira KS, Schmidt FL, Guaraldo AM, et al. Chagas' disease as a foodborne illness. J Food Prot 2009; 72:441.</a></li><li><a class="nounderline abstract_t">Shikanai-Yasuda MA, Carvalho NB. Oral transmission of Chagas disease. Clin Infect Dis 2012; 54:845.</a></li><li><a class="nounderline abstract_t">Alarcón de Noya B, Díaz-Bello Z, Colmenares C, et al. Large urban outbreak of orally acquired acute Chagas disease at a school in Caracas, Venezuela. J Infect Dis 2010; 201:1308.</a></li><li><a class="nounderline abstract_t">Nóbrega AA, Garcia MH, Tatto E, et al. Oral transmission of Chagas disease by consumption of açaí palm fruit, Brazil. Emerg Infect Dis 2009; 15:653.</a></li><li><a class="nounderline abstract_t">Roellig DM, Ellis AE, Yabsley MJ. Oral transmission of Trypanosoma cruzi with opposing evidence for the theory of carnivory. J Parasitol 2009; 95:360.</a></li><li><a class="nounderline abstract_t">PEDREIRA DE FREITAS JL, AMATO NETO V, SONNTAG R, et al. [First tests on the accidental transmission of Chagas disease to man by blood transfusion]. Rev Paul Med 1952; 40:36.</a></li><li><a class="nounderline abstract_t">Wendel S, Leiby DA. Parasitic infections in the blood supply: assessing and countering the threat. Dev Biol (Basel) 2007; 127:17.</a></li><li><a class="nounderline abstract_t">Benjamin RJ, Stramer SL, Leiby DA, et al. Trypanosoma cruzi infection in North America and Spain: evidence in support of transfusion transmission. Transfusion 2012; 52:1913.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Blood donor screening for chagas disease--United States, 2006-2007. MMWR Morb Mortal Wkly Rep 2007; 56:141.</a></li><li><a class="nounderline abstract_t">Cimo PL, Luper WE, Scouros MA. Transfusion-associated Chagas' disease in Texas: report of a case. Tex Med 1993; 89:48.</a></li><li><a class="nounderline abstract_t">Leiby DA, Lenes BA, Tibbals MA, Tames-Olmedo MT. Prospective evaluation of a patient with Trypanosoma cruzi infection transmitted by transfusion. N Engl J Med 1999; 341:1237.</a></li><li><a class="nounderline abstract_t">Young C, Losikoff P, Chawla A, et al. Transfusion-acquired Trypanosoma cruzi infection. Transfusion 2007; 47:540.</a></li><li><a class="nounderline abstract_t">Riarte A, Luna C, Sabatiello R, et al. Chagas' disease in patients with kidney transplants: 7 years of experience 1989-1996. Clin Infect Dis 1999; 29:561.</a></li><li><a class="nounderline abstract_t">Kun H, Moore A, Mascola L, et al. Transmission of Trypanosoma cruzi by heart transplantation. Clin Infect Dis 2009; 48:1534.</a></li><li><a class="nounderline abstract_t">Cicora F, Escurra V, Silguero S, et al. Use of kidneys from trypanosoma cruzi-infected donors in naive transplant recipients without prophylactic therapy: the experience in a high-risk area. Transplantation 2014; 97:e3.</a></li><li><a class="nounderline abstract_t">Chin-Hong PV, Schwartz BS, Bern C, et al. Screening and treatment of chagas disease in organ transplant recipients in the United States: recommendations from the chagas in transplant working group. Am J Transplant 2011; 11:672.</a></li><li><a class="nounderline abstract_t">Forés R, Sanjuán I, Portero F, et al. Chagas disease in a recipient of cord blood transplantation. Bone Marrow Transplant 2007; 39:127.</a></li><li><a class="nounderline abstract_t">Herwaldt BL. Laboratory-acquired parasitic infections from accidental exposures. Clin Microbiol Rev 2001; 14:659.</a></li><li><a class="nounderline abstract_t">Rabinovich JE, Wisnivesky-Colli C, Solarz ND, Gürtler RE. Probability of transmission of Chagas disease by Triatoma infestans (Hemiptera: Reduviidae) in an endemic area of Santiago del Estero, Argentina. Bull World Health Organ 1990; 68:737.</a></li><li><a class="nounderline abstract_t">Nouvellet P, Dumonteil E, Gourbière S. The improbable transmission of Trypanosoma cruzi to human: the missing link in the dynamics and control of Chagas disease. PLoS Negl Trop Dis 2013; 7:e2505.</a></li><li><a class="nounderline abstract_t">Carter YL, Juliano JJ, Montgomery SP, Qvarnstrom Y. Acute Chagas disease in a returning traveler. Am J Trop Med Hyg 2012; 87:1038.</a></li><li><a class="nounderline abstract_t">Kroeger A, Villegas E, Ordoñez-González J, et al. Prevention of the transmission of Chagas' disease with pyrethroid-impregnated materials. Am J Trop Med Hyg 2003; 68:307.</a></li><li><a class="nounderline abstract_t">Rassi A Jr, Dias JC, Marin-Neto JA, Rassi A. Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas' disease. Heart 2009; 95:524.</a></li><li><a class="nounderline abstract_t">Dias JC, Silveira AC, Schofield CJ. The impact of Chagas disease control in Latin America: a review. Mem Inst Oswaldo Cruz 2002; 97:603.</a></li><li><a class="nounderline abstract_t">Congenital infection with Trypanosoma cruzi: from mechanisms of transmission to strategies for diagnosis and control. Rev Soc Bras Med Trop 2003; 36:767.</a></li><li><a class="nounderline abstract_t">Blanco SB, Segura EL, Gürtler RE. [Control of congenital transmission of Trypanosoma cruzi in Argentina]. Medicina (B Aires) 1999; 59 Suppl 2:138.</a></li><li><a class="nounderline abstract_t">Gonçalves R, Landivar D, Grover Sañez Liendo E, et al. Improving houses in the Bolivian Chaco increases effectiveness of residual insecticide spraying against infestation with Triatoma infestans, vector of Chagas disease. Trop Med Int Health 2021; 26:1127.</a></li><li><a class="nounderline abstract_t">Moncayo A. Chagas disease: current epidemiological trends after the interruption of vectorial and transfusional transmission in the Southern Cone countries. Mem Inst Oswaldo Cruz 2003; 98:577.</a></li><li><a class="nounderline abstract_t">Moncayo A, Ortiz Yanine MI. An update on Chagas disease (human American trypanosomiasis). Ann Trop Med Parasitol 2006; 100:663.</a></li><li><a class="nounderline abstract_t">Dias JC. Southern Cone Initiative for the elimination of domestic populations of Triatoma infestans and the interruption of transfusional Chagas disease. Historical aspects, present situation, and perspectives. Mem Inst Oswaldo Cruz 2007; 102 Suppl 1:11.</a></li><li><a class="nounderline abstract_t">Gürtler RE, Kitron U, Cecere MC, et al. Sustainable vector control and management of Chagas disease in the Gran Chaco, Argentina. Proc Natl Acad Sci U S A 2007; 104:16194.</a></li><li><a class="nounderline abstract_t">Klotz SA, Dorn PL, Mosbacher M, Schmidt JO. Kissing bugs in the United States: risk for vector-borne disease in humans. Environ Health Insights 2014; 8:49.</a></li><li><a class="nounderline abstract_t">Schmuñis GA. Trypanosoma cruzi, the etiologic agent of Chagas' disease: status in the blood supply in endemic and nonendemic countries. Transfusion 1991; 31:547.</a></li><li><a class="nounderline abstract_t">Schmunis GA, Cruz JR. Safety of the blood supply in Latin America. Clin Microbiol Rev 2005; 18:12.</a></li><li><a class="nounderline abstract_t">Leiby DA, Read EJ, Lenes BA, et al. Seroepidemiology of Trypanosoma cruzi, etiologic agent of Chagas' disease, in US blood donors. J Infect Dis 1997; 176:1047.</a></li><li class="breakAll">US Food and Drug Administration. Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Blood and Blood Components. https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/UCM528600.pdf (Accessed on November 11, 2021).</li><li><a class="nounderline abstract_t">Forsyth CJ, Manne-Goehler J, Bern C, et al. Recommendations for Screening and Diagnosis of Chagas Disease in the United States. J Infect Dis 2022; 225:1601.</a></li><li><a class="nounderline abstract_t">Castro-Sesquen YE, Saldaña A, Patino Nava D, et al. Use of a Latent Class Analysis in the Diagnosis of Chronic Chagas Disease in the Washington Metropolitan Area. Clin Infect Dis 2021; 72:e303.</a></li><li class="breakAll">Manne-Goehler J, Davis J, Perez JH, et al. The results of a primary care-based screening program for Trypanosoma cruzi in East Boston, Massachusetts. IDWeek, 2018. San Francisco, CA.</li><li><a class="nounderline abstract_t">Manne-Goehler J, Umeh CA, Montgomery SP, Wirtz VJ. Estimating the Burden of Chagas Disease in the United States. PLoS Negl Trop Dis 2016; 10:e0005033.</a></li><li><a class="nounderline abstract_t">Nunes MCP, Beaton A, Acquatella H, et al. Chagas Cardiomyopathy: An Update of Current Clinical Knowledge and Management: A Scientific Statement From the American Heart Association. Circulation 2018; 138:e169.</a></li><li><a class="nounderline abstract_t">Messenger LA, Bern C. Congenital Chagas disease: current diagnostics, limitations and future perspectives. Curr Opin Infect Dis 2018; 31:415.</a></li><li><a class="nounderline abstract_t">Sánchez Negrette O, Mora MC, Basombrío MA. High prevalence of congenital Trypanosoma cruzi infection and family clustering in Salta, Argentina. Pediatrics 2005; 115:e668.</a></li><li><a class="nounderline abstract_t">Messenger LA, Gilman RH, Verastegui M, et al. Toward Improving Early Diagnosis of Congenital Chagas Disease in an Endemic Setting. Clin Infect Dis 2017; 65:268.</a></li><li><a class="nounderline abstract_t">Perez-Zetune V, Bialek SR, Montgomery SP, Stillwaggon E. Congenital Chagas Disease in the United States: The Effect of Commercially Priced Benznidazole on Costs and Benefits of Maternal Screening. Am J Trop Med Hyg 2020; 102:1086.</a></li><li><a class="nounderline abstract_t">Edwards MS, Rench MA, Todd CW, et al. Perinatal Screening for Chagas Disease in Southern Texas. J Pediatric Infect Dis Soc 2015; 4:67.</a></li><li><a class="nounderline abstract_t">Di Pentima MC, Hwang LY, Skeeter CM, Edwards MS. Prevalence of antibody to Trypanosoma cruzi in pregnant Hispanic women in Houston. Clin Infect Dis 1999; 28:1281.</a></li><li><a class="nounderline abstract_t">Ramos JM, Milla A, Sánchez V, et al. [Prenatal screening for Trypanosoma cruzi and human T lymphotropic virus types 1 and 2 in pregnant Latin American women]. Enferm Infecc Microbiol Clin 2009; 27:165.</a></li><li><a class="nounderline abstract_t">Luquetti AO, Dias JC, Prata A. [Diagnosis and treatment of congenital infection caused by Trypanosoma cruzi in Brazil]. Rev Soc Bras Med Trop 2005; 38 Suppl 2:27.</a></li><li><a class="nounderline abstract_t">Feilij H, Muller L, Gonzalez Cappa SM. Direct micromethod for diagnosis of acute and congenital Chagas' disease. J Clin Microbiol 1983; 18:327.</a></li><li class="breakAll">Programa Nacional de Control de Chagas. Chagas Congénito: Estrategias de Diagnóstico y Control. 2nd ed: Digital Dreams, Cochabamba, Bolivia, 2007:1-89.</li><li><a class="nounderline abstract_t">Alonso-Vega C, Billot C, Torrico F. Achievements and challenges upon the implementation of a program for national control of congenital Chagas in Bolivia: results 2004-2009. PLoS Negl Trop Dis 2013; 7:e2304.</a></li><li><a class="nounderline abstract_t">Blanco SB, Segura EL, Cura EN, et al. Congenital transmission of Trypanosoma cruzi: an operational outline for detecting and treating infected infants in north-western Argentina. Trop Med Int Health 2000; 5:293.</a></li><li><a class="nounderline abstract_t">Benchetrit AG, Fernández M, Bava AJ, et al. Clinical and epidemiological features of chronic Trypanosoma cruzi infection in patients with HIV/AIDS in Buenos Aires, Argentina. Int J Infect Dis 2018; 67:118.</a></li><li><a class="nounderline abstract_t">Morillo CA, Marin-Neto JA, Avezum A, et al. Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. N Engl J Med 2015; 373:1295.</a></li><li><a class="nounderline abstract_t">Gray EB, La Hoz RM, Green JS, et al. Reactivation of Chagas disease among heart transplant recipients in the United States, 2012-2016. Transpl Infect Dis 2018; 20:e12996.</a></li></ol></div><div id="topicVersionRevision">Topic 5698 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28673423" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Chagas disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26222561" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Chagas' Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31776135" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Chagas Disease in the United States: a Public Health Approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31776135" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Chagas Disease in the United States: a Public Health Approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20399979" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Chagas disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25671846" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Chagas disease in Latin America: an epidemiological update based on 2010 estimates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Revision of the Triatominae (Hemiptera, Reduviidae), and their significance as vectors of Chagas' disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Revision of the Triatominae (Hemiptera, Reduviidae), and their significance as vectors of Chagas' disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11998705" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Emerging Chagas disease in Amazonian Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11474111" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Modeling household transmission of American trypanosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9660458" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Influence of humans and domestic animals on the household prevalence of Trypanosoma cruzi in Triatoma infestans populations in northwest Argentina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14187892" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : CHAGAS' DISEASE IN PERU. I. THE EPIDEMIOLOGICAL IMPORTANCE OF THE GUINEA PIG.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12829559" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : American trypanosomiasis (Chagas' disease) and the role of molecular epidemiology in guiding control strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19385053" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Classification, evolution, and species groups within the Triatominae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19691868" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The molecular epidemiology and phylogeography of Trypanosoma cruzi and parallel research on Leishmania: looking back and to the future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22357219" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Elimination of Rhodnius prolixus in Central America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22357219" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Elimination of Rhodnius prolixus in Central America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17073082" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Periurban Trypanosoma cruzi-infected Triatoma infestans, Arequipa, Peru.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/103445" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : House construction, triatomine distribution, and household distribution of seroreactivity to Trypanosoma cruzi in a rural community in northeast Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14640497" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Seroprevalence and risk factors for Trypanosoma cruzi infection in the Amazon region of Ecuador.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1449194" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The epidemiology of Chagas' disease in a hyperendemic area of Cochabamba, Bolivia: a clinical study including electrocardiography, seroreactivity to Trypanosoma cruzi, xenodiagnosis, and domiciliary triatomine distribution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12488226" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Chagas disease control in Venezuela: lessons for the Andean region and beyond.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23936581" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Epidemiology of and impact of insecticide spraying on Chagas disease in communities in the Bolivian Chaco.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/822736" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The epidemiology and household distribution of seroreactivity to Trypanosoma cruzi in a rural community in northeast Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/822736" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The epidemiology and household distribution of seroreactivity to Trypanosoma cruzi in a rural community in northeast Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3552307" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cardiac morbidity and mortality due to Chagas' disease: prospective electrocardiographic study of a Brazilian community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26407511" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Electrocardiographic and echocardiographic abnormalities in Chagas disease: findings in residents of rural Bolivian communities hyperendemic for Chagas disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12533289" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Chagas disease in a domestic transmission cycle, southern Texas, USA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18255233" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Distribution and characterization of canine Chagas disease in Texas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11838232" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Seroprevalence of Trypanosoma cruzi in raccoons from South Carolina and Georgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20202413" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Infection of kissing bugs with Trypanosoma cruzi, Tucson, Arizona, USA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17553277" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Autochthonous transmission of Trypanosoma cruzi, Louisiana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3919598" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Human and sylvatic Trypanosoma cruzi infection in California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8644910" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Postmortem diagnosis of autochthonous acute chagasic myocarditis by polymerase chain reaction amplification of a species-specific DNA sequence of Trypanosoma cruzi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6425516" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Indigenous Chagas' disease (American trypanosomiasis) in California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13263111" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : American trypanosomiasis (Chagas' disease); first indigenous case in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18803501" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Detection of Blastocrithidia spp. (Kinetoplastida: Trypanosomatidae) in Chagas disease vectors from Texas, USA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25371187" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Evidence of autochthonous Chagas disease in southeastern Texas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32078594" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Autochthonous Chagas Disease - Missouri, 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19524078" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Feeding behavior of triatomines from the southwestern United States: an update on potential risk for transmission of Chagas disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30588627" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Impact of one-time testing for Trypanosoma cruzi antibodies among blood donors in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19640226" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : An estimate of the burden of Chagas disease in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19646412" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Chagas disease in Spain, the United States and other non-endemic countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19877966" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Congenital Trypanosoma cruzi transmission in Santa Cruz, Bolivia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20502520" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Chagas cardiomyopathy in the context of the chronic disease transition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29975678" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Chagas Disease Surveillance Activities - Seven States, 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28329123" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Prevalence of Chagas Disease in the Latin American-born Population of Los Angeles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23537911" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Chagas disease in Latin American immigrants with dilated cardiomyopathy in New York City.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26206855" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Prevalence and Impact of Chagas Disease Among Latin American Immigrants With Nonischemic Cardiomyopathy in Los Angeles, California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28056014" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prevalence of Chagas Disease in a U.S. Population of Latin American Immigrants with Conduction Abnormalities on Electrocardiogram.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28500812" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The Prevalence of Chagas Disease Among Latin American Immigrants with Pacemakers in Los Angeles, California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25680190" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Prevalence of Chagas disease in Latin-American migrants living in Europe: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18725796" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Chagas disease and the US blood supply.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22404755" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The United States Trypanosoma cruzi Infection Study: evidence for vector-borne transmission of the parasite that causes Chagas disease among United States blood donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19331743" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Congenital transmission of Chagas disease in Latin American immigrants in Switzerland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17655897" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Congenital Trypanosoma cruzi infection in a non-endemic area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21976603" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Trypanosoma cruzi and Chagas' Disease in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22763884" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Congenital transmission of Chagas disease - Virginia, 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23837488" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Donor-derived Trypanosoma cruzi infection in solid organ recipients in the United States, 2001-2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22231251" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Co-infection Trypanosoma cruzi/HIV: systematic review (1980-2010).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20034346" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A woman with HIV infection, brain abscesses, and eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22614520" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Chagas disease in the immunosuppressed host.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18337139" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Reactivation of Chagas disease with central nervous system involvement in HIV-infected patients in Argentina, 1992-2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26919324" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Use of a Chagas Urine Nanoparticle Test (Chunap) to Correlate with Parasitemia Levels in T. cruzi/HIV Co-infected Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19753458" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Sustainability of vector control strategies in the Gran Chaco Region: current challenges and possible approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18430443" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Epidemiological evaluation of Chagas disease in a rural area of southern Bolivia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6113312" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Do radically dissimilar Trypanosoma cruzi strains (zymodemes) cause Venezuelan and Brazilian forms of Chagas' disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22226704" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The revised Trypanosoma cruzi subspecific nomenclature: rationale, epidemiological relevance and research applications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28941731" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Trypanosoma cruzi genetic diversity: Something new for something known about Chagas disease manifestations, serodiagnosis and drug sensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21152056" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Chagas cardiomyopathy manifestations and Trypanosoma cruzi genotypes circulating in chronic Chagasic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22745843" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Geographical distribution of Trypanosoma cruzi genotypes in Venezuela.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23421890" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Microsatellite and mini-exon analysis of Mexican human DTU I Trypanosoma cruzi strains and their susceptibility to nifurtimox and benznidazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26162928" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Between a bug and a hard place: Trypanosoma cruzi genetic diversity and the clinical outcomes of Chagas disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24852444" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Development of peptide-based lineage-specific serology for chronic Chagas disease: geographical and clinical distribution of epitope recognition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29438471" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Severity of Chagasic Cardiomyopathy Is Associated With Response to a Novel Rapid Diagnostic Test for Trypanosoma cruzi TcII/V/VI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33009443" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Glycosylation of Trypanosoma cruzi TcI antigen reveals recognition by chagasic sera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11558005" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Congenital Chagas disease of second generation in Santiago, Chile. Report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14993634" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Maternal Trypanosoma cruzi infection, pregnancy outcome, morbidity, and mortality of congenitally infected and non-infected newborns in Bolivia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16482810" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : [Congenital transmission of Trypanosoma cruzi infection in Argentina].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16482810" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : [Congenital transmission of Trypanosoma cruzi infection in Argentina].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1841425" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : [Prospective study of Chagas disease in newborn children with placental infection caused by Trypanosoma cruzi (Santa Cruz-Bolivia)].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10668257" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : [The transmission de Chagas disease in Salta and the detection of congenital cases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23097582" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Risk factors and primary prevention of congenital Chagas disease in a nonendemic country.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23924273" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Frequency of the congenital transmission of Trypanosoma cruzi: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26063720" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Sustained Domestic Vector Exposure Is Associated With Increased Chagas Cardiomyopathy Risk but Decreased Parasitemia and Congenital Transmission Risk Among Young Women in Bolivia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28201741" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Treatment of Infected Women of Childbearing Age Prevents Congenital Trypanosoma cruzi Infection by Eliminating the Parasitemia Detected by PCR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1342103" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Possible risk factors for vertical transmission of Chagas' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8527542" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Congenital Chagas' disease: diagnostic and clinical aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6805103" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : The influence of the strain of Trypanosoma cruzi in placental infections in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17620638" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Comparison of Trypanosoma cruzi lineages and levels of parasitic DNA in infected mothers and their newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19967227" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Etiological treatment of young women infected with Trypanosoma cruzi, and prevention of congenital transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25411847" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Trypanocide treatment of women infected with Trypanosoma cruzi and its effect on preventing congenital Chagas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27516969" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Congenital Chagas' disease transmission in the United States: Diagnosis in adulthood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24050257" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Chagas disease and breast-feeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3150483" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Evaluation of Chagas' disease transmission through breast-feeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19350996" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Chagas' disease as a foodborne illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22238161" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Oral transmission of Chagas disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20307205" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Large urban outbreak of orally acquired acute Chagas disease at a school in Caracas, Venezuela.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19331764" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Oral transmission of Chagas disease by consumption of açaípalm fruit, Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18763853" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Oral transmission of Trypanosoma cruzi with opposing evidence for the theory of carnivory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14942150" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : [First tests on the accidental transmission of Chagas disease to man by blood transfusion].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17486879" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Parasitic infections in the blood supply: assessing and countering the threat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22321142" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Trypanosoma cruzi infection in North America and Spain: evidence in support of transfusion transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17318113" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Blood donor screening for chagas disease--United States, 2006-2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8178305" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Transfusion-associated Chagas' disease in Texas: report of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10523159" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Prospective evaluation of a patient with Trypanosoma cruzi infection transmitted by transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17319837" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Transfusion-acquired Trypanosoma cruzi infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10530448" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Chagas' disease in patients with kidney transplants: 7 years of experience 1989-1996.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19400748" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Transmission of Trypanosoma cruzi by heart transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24374767" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Use of kidneys from trypanosoma cruzi-infected donors in naive transplant recipients without prophylactic therapy: the experience in a high-risk area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21401868" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Screening and treatment of chagas disease in organ transplant recipients in the United States: recommendations from the chagas in transplant working group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17213850" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Chagas disease in a recipient of cord blood transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11585780" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Laboratory-acquired parasitic infections from accidental exposures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2127382" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Probability of transmission of Chagas disease by Triatoma infestans (Hemiptera: Reduviidae) in an endemic area of Santiago del Estero, Argentina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24244766" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : The improbable transmission of Trypanosoma cruzi to human: the missing link in the dynamics and control of Chagas disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23091192" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Acute Chagas disease in a returning traveler.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12685636" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Prevention of the transmission of Chagas' disease with pyrethroid-impregnated materials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19131444" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12219120" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : The impact of Chagas disease control in Latin America: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15143784" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Congenital infection with Trypanosoma cruzi: from mechanisms of transmission to strategies for diagnosis and control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10668256" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : [Control of congenital transmission of Trypanosoma cruzi in Argentina].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34114721" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Improving houses in the Bolivian Chaco increases effectiveness of residual insecticide spraying against infestation with Triatoma infestans, vector of Chagas disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12973523" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Chagas disease: current epidemiological trends after the interruption of vectorial and transfusional transmission in the Southern Cone countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17227647" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : An update on Chagas disease (human American trypanosomiasis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17891281" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Southern Cone Initiative for the elimination of domestic populations of Triatoma infestans and the interruption of transfusional Chagas disease. Historical aspects, present situation, and perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17913895" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Sustainable vector control and management of Chagas disease in the Gran Chaco, Argentina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25574143" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Kissing bugs in the United States: risk for vector-borne disease in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1906650" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Trypanosoma cruzi, the etiologic agent of Chagas' disease: status in the blood supply in endemic and nonendemic countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15653816" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Safety of the blood supply in Latin America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9333165" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Seroepidemiology of Trypanosoma cruzi, etiologic agent of Chagas' disease, in US blood donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9333165" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Seroepidemiology of Trypanosoma cruzi, etiologic agent of Chagas' disease, in US blood donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34623435" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Recommendations for Screening and Diagnosis of Chagas Disease in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32766826" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Use of a Latent Class Analysis in the Diagnosis of Chronic Chagas Disease in the Washington Metropolitan Area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32766826" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Use of a Latent Class Analysis in the Diagnosis of Chronic Chagas Disease in the Washington Metropolitan Area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27820837" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Estimating the Burden of Chagas Disease in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30354432" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Chagas Cardiomyopathy: An Update of Current Clinical Knowledge and Management: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30095485" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Congenital Chagas disease: current diagnostics, limitations and future perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15930194" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : High prevalence of congenital Trypanosoma cruzi infection and family clustering in Salta, Argentina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28369287" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Toward Improving Early Diagnosis of Congenital Chagas Disease in an Endemic Setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32100696" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Congenital Chagas Disease in the United States: The Effect of Commercially Priced Benznidazole on Costs and Benefits of Maternal Screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26407360" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Perinatal Screening for Chagas Disease in Southern Texas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10451166" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Prevalence of antibody to Trypanosoma cruzi in pregnant Hispanic women in Houston.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19306717" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : [Prenatal screening for Trypanosoma cruzi and human T lymphotropic virus types 1 and 2 in pregnant Latin American women].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16482809" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : [Diagnosis and treatment of congenital infection caused by Trypanosoma cruzi in Brazil].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6413530" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Direct micromethod for diagnosis of acute and congenital Chagas' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6413530" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Direct micromethod for diagnosis of acute and congenital Chagas' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23875039" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Achievements and challenges upon the implementation of a program for national control of congenital Chagas in Bolivia: results 2004-2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10810029" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Congenital transmission of Trypanosoma cruzi: an operational outline for detecting and treating infected infants in north-western Argentina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29196277" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Clinical and epidemiological features of chronic Trypanosoma cruzi infection in patients with HIV/AIDS in Buenos Aires, Argentina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26323937" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30204269" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Reactivation of Chagas disease among heart transplant recipients in the United States, 2012-2016.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
